Last updated: April 25, 2026
Who Supplies Glucagon Hydrochloride to the Pharmaceutical Supply Chain?
What is the relevant market for “glucagon hydrochloride” supply?
“Glucagon hydrochloride” is typically sourced in two forms:
- Drug substance (API): glucagon (often discussed in practice as glucagon for peptide drugs; the salt form is used for product specs and labeling).
- Finished drug product: injectable glucagon for emergency treatment of severe hypoglycemia.
Because glucagon is a specialty peptide with tight regulatory controls, procurement commonly runs through API manufacturers with peptide capability or finished-dose brands/licensed suppliers, not general chemical suppliers.
Which supplier categories exist?
- API manufacturers (peptide manufacturing and purification; supply of glucagon as API for branded or generic manufacturers)
- Finished-dose manufacturers (injection products, typically licensed and distributed through national wholesalers)
- Contract manufacturing organizations (CMOs) supporting peptide API and sterile drug product development (capability-driven supply, not always a direct “supplier name” in public listings)
API and Finished-Dose Suppliers: Practical Procurement Targets
Who makes glucagon products (finished-dose supply) in key regulated markets?
Finished glucagon is supplied by brand owners and their marketing authorizations (which often drive availability through large distributors). The best documented “supplier” relationships in public sources are typically tied to the approved products and their marketing authorization holders rather than raw peptide salts.
Key internationally used glucagon injection products include:
- GlucaGen® (glucagon for injection) by Novo Nordisk
- Baqsimi® (nasal glucagon) by Eli Lilly (different route, same active moiety; included because procurement often treats glucagon as an interchange category when planning severe hypoglycemia supply)
- Zegalogue® (dasiglucagon, not glucagon hydrochloride; included in market context because it appears in “glucagon” procurement discussions but is a different active ingredient)
For explicit glucagon hydrochloride injection supply planning, the most directly relevant finished-dose supplier record is Novo Nordisk for GlucaGen® (glucagon hydrochloride product line).
Who supplies glucagon hydrochloride at API level (peptide drug substance)?
In the absence of a single consolidated global “glucagon hydrochloride API supplier list” published in a standardized procurement format, API sourcing is typically verified through:
- DMF/CEP/EDQM dossiers
- Regulatory filings and manufacturer-of-record references
- Direct supplier qualification by the buyer
Publicly indexed supplier directories frequently list glucagon API suppliers, but those lists are not consistently complete and change over time. For procurement decisions, teams usually validate candidate suppliers against regulatory documentation (DMF holders, CEP holders, or marketing authorization submissions).
Supplier Identification and Due-Diligence Checklist (Procurement-Ready)
What to verify for glucagon hydrochloride supply?
A procurement shortlist should be constrained to suppliers who can demonstrate compliance across peptide-specific and injectable-specific requirements:
API (glucagon hydrochloride) qualification checks
- Peptide drug substance capability (solid-phase peptide synthesis, purification, correct handling of oxidation and impurity profile)
- Potency and impurity control (HPLC/UPLC release specs, peptide-related impurities, fragment profile)
- Salt form handling (glucagon hydrochloride specifications consistent with the buyer’s finished product monograph or internal target profile)
- Stability data for peptide at expected storage conditions and packaging configuration
Sterile finished drug product checks (if sourcing finished-dose)
- Sterile manufacturing and aseptic processing (sterility assurance level and batch release approach)
- Container closure system suitability (for reconstitution kits and emergency use packaging)
- Cold chain requirements (if any) and transport stability for emergency procurement
Actionable Supplier Targets (Name-Backed Procurement Roles)
Finished-dose supplier with explicit glucagon injection line
- Novo Nordisk: GlucaGen® (glucagon for injection; glucagon hydrochloride is the relevant active form in this product line) [1]
Procurement adjacency: glucagon platform supplier role (non-hydrochloride)
- Eli Lilly: Baqsimi® (nasal glucagon; used for severe hypoglycemia access planning, not glucagon hydrochloride API for injection) [2]
Market Context: Why “Supplier” Lists Differ by Source
Procurement searches for “glucagon hydrochloride suppliers” can return:
- API producers (often listed as “glucagon,” with salt form set in product specifications)
- Finished-dose manufacturers (branded products tied to active form specs)
- Distributors/resellers (not actual manufacturers)
For high-stakes supply continuity, operationally meaningful supplier selection is the manufacturing-of-record for either:
- API dossiers, or
- finished-dose marketing authorizations.
Key Takeaways
- Novo Nordisk is the clearest name-linked supplier for glucagon hydrochloride injection via GlucaGen®. [1]
- Many procurement databases list “glucagon” rather than “glucagon hydrochloride” as the API name; practical qualification must tie to salt-form specifications and regulatory documentation.
- “Glucagon” availability planning often extends beyond injection to nasal glucagon platforms (e.g., Baqsimi®), which are supplied by Eli Lilly but are not glucagon hydrochloride. [2]
FAQs
1) Are glucagon hydrochloride and glucagon the same substance for sourcing?
In practice, API sourcing commonly lists “glucagon,” while the finished-dose specification and labeling reference the hydrochloride salt form for glucagon for injection products. Supplier qualification must be tied to the buyer’s required salt-form specifications and regulatory dossier content.
2) Who is the main supplier for glucagon injection in major markets?
Novo Nordisk supplies GlucaGen® (glucagon for injection), the brand line used for severe hypoglycemia treatment in many jurisdictions. [1]
3) Do nasal glucagon products count as glucagon hydrochloride supply?
No. Baqsimi® is nasal glucagon and is supplied by Eli Lilly, but it is not glucagon hydrochloride injection. It is used as a different route option in severe hypoglycemia planning. [2]
4) Can procurement rely on general chemical distributors for glucagon hydrochloride API?
For API supply, buyers typically require regulatory documentation (DMF/CEP and release specifications). Distributor availability alone is not sufficient for peptide APIs without verified manufacturing-of-record evidence.
5) What documentation should tie to the chosen supplier?
Procurement should align supplier selection to regulatory dossier identifiers and release specs matching the intended route and finished product standard, including salt-form and impurity/potency criteria.
References
[1] Novo Nordisk. (n.d.). GlucaGen® (glucagon for injection) product information.
[2] Eli Lilly and Company. (n.d.). Baqsimi® (glucagon) product information.
